powerpoint-präsentation · pdf filesecond world war. mid-90s positioning as ... ergonomic...

1

Company PresentationApril 2017

Agenda

Sartorius in Brief01

03 Lab Products & Services

Bioprocess Solutions02

04 Sartorius 2020

05 Appendix

Sartorius in 2016

Figures as of Dec. 31, 2016; 1 Underlying EBITDA (excluding extraordinary items)

~€325 mnEarnings1

~€1.3 bnSales revenue

Bioprocess and Laboratory Technologies Provider

Internationally leading

EBITDA1 margin

Sales revenue by region

~€152 mnInvestments

~34%Americas

~44%EMEA

~22%Asia | Pacific

25.0 %

Listed since 1990; Part of German TecDax

3

More than 6,900 Employees Worldwide

Figures as of Dec. 31, 2016 5

~1,000Americas

~4,850EMEA

~1,050Asia|Pacific

Discover Sartorius1995

1996

~7,0003,000 4,000 5,0002,000

1997 1998 1999 2001 20062002 2003 2004 2005 2008 20132009 2010 2011 2014

2000 2007 2012 20152016

2017

https://www.youtube.com/watch?v=2UR7i8jH4Nc



Our Corporate Values

6

Roots of Both Divisions Reach Far Back

Weighing TechnologyCore of Lab Division

Filtration Mainstay of Bioprocess Division

University mechanician | Company founder Florenz Sartorius invents short-beam analytical balance

Wilhelm Sartorius founds joint venture with Nobel laureate and creator of membrane filtrationRichard Zsigmondy

1870 1927

7

8

1870 Florenz Sartorius foundsprecision machine workshop

2007 Biotechnology Division merges withStedim to Sartorius Stedim Biotech1927 Membrane filter

company is founded2011 New Division Lab Products & Services; Acquisition Biohit LH

since 2012 Six Acquisitionsin Bioprocess Solutions1990 Initial public

offering

Rebuilding after Second World War

Mid-90s Positioning asbiopharma supplier

2000 Acquisitionof B. Braun‘s fer-mentation business

Core companyin Goettingen

Expansion into Asia Around 50 sitesworldwide

Internationaldistribution

Subsidiaries in Europe | North America

1870 199519801930 Today

Business Development Spanning More Than 140 Years

2016 Acquisitions ofIntelliCyt and ViroCyt

2017 Acquisitions ofEssen BioScience andUmetrics

Two Divisions

Share of Group sales based on figures as of Dec. 31, 2016 9

Premium lab instruments, consumables and services for R&D, QA and QC

Lab Products & ServicesBioprocess Solutions

~75%of sales

~25%of sales

Innovative single-use prodcts andequipment for the manufacture of biologics

Agenda




04 Sartorius 2020

05 Appendix

What Are Biopharmaceuticals?

11

First-time or improved treatment of serious illnesses, such as cancer, multiple sclerosis, rheumatism Targets only diseased cells; fewer side effects New vaccines

~20.000 Atoms

R&D and production labor-intensive

High therapy costs: biologics ~ $50 vs. chemical medications ~ $2 per day

Living, geneticallymodified cells Production Injection | Infusion

Advantages Challenges

High initial cost

Considerable cleaning effort

Risk of cross-contamination

12

Trend towards Manufacturing Single-use Technologies

PresentPast

+ CAPEX reduction over entire lifecycle

+ Lower water and energy consumption

+ Higher flexibility

BPS Generates Around 75% of its Business with Single-use Products

~ €975mn.Single-use~ 75 %

Equipment~25 %

13Figures as of Dec. 31, 2016

Total Solution Provider across the Biopharma Process Chain

14

Services

Process Development Production

Fermentation PurificationCell Harvesting Buffer | PreparationCell Culture Media

Leading Market Positions Worldwide

>85 % of sales revenue generated from TOP 1-3 positions

Filtration TOP 3 Fluid Management #1 Fermentation #1

15

Agenda




04 Sartorius 2020

05 Appendix

Research Labs Need Intelligent Lab Instruments

17

Assistance systems reduce user errors

Laboratory data are processedautomatically

Ergonomic design minimizes physicalstrain

Quality Assurance Labs Accompany every Step of Food andPharma Production

18

Sample collection

Quality assurance

Clearance

Documentation

These Products and Services are Must-Haves in Any Laboratory

19

Balances Pipettes Lab Water Systems Moisture Analyzers

Lab Instruments Consumables Services Syringe Filters Microbiological

Test Kits Pipette Tips

Installation Servicing | Repair Qualification (IQ/OQ) Calibration Training

Lab Portfolio Recently Expanded into Bioanalytics

20

Innovative and unique bioanalytical platforms, combined from instruments, reagents and software

Focus on customers from pharma/biotech and academia

Excellent fit between the two acquired companies and with existing LPS portfolio

Award-winning technology for cell screening

Unique system for real-timelive-cell imaging and analysis

Acquisition in June 2016

Acquisition in July 2016

Acquisition in April 2017

Innovative platform for rapid virus quantification

Expansion of Direct Sales including eBusiness

Distributors

optimize

Direct salesexpand

eBusinessbuild upSa

les

Chan

nels

Pharma | Biotech

Academia

Cl. Diagnostics | Chemicals

Food & Beverage

Leading Market Positions Worldwide

Average global market share >10%

Significant growth potential, especially in USA and Asia

Lab Balances #2 Pipettes #4 Lab Filtration #3 Microb. Analysis #2(membrane based)

22

Agenda




04 Sartorius 2020

05 Appendix

Profitable Growth in Past 10 Years

1Underlying EBITDA (adjusted for extraordinary items); 2 Including Intec (Intec sales revenue = shaded area) 24

521.1

622.7 611.6 602.1659.3

733.1

845.7887.3 891.2

13.715.3

13.114.1

16.718.6 19.0 19.5

21.0

23.625.0

0

5

10

15

20

25

30

35

40

2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 20162

Sales revenue € in mn Underlying EBITDA1 margin in %

1,300.3

1,114.8

Ambitious Growth Targets Up to 2020

1 Based on 2015 exchange rates; 2 Excluding extraordinary items 25

Regional North America: Gain market share Asia | esp. China: Leverage strong market growth

Strategic Initiatives 2020 Targets

Portfolio Expansion through alliances and acquisitions Own product development

Infrastructure Expansion of production capacity New global ERP system

~€2bn.Sales Revenue

~26 - 27% EBITDA2 margin

~3/4Organic

~1/4 Acquisitions

1

1

Gain Market Share in North America; Leverage Strong Market Growth in Asia

1 2011-2016, in constant currencies 2 Figures as of Dec. 31, 2016 26

Sales share2

Americas

Asia | Pacific

~€1.3 bn.

34%

22%

Regional

~+18%CAGR1 Americas

~+14%CAGR1 Asia | Pacific

North America: largest market for biopharma and lab products

Asia: strongest-growing pharma and lab market

Mississauga

Mexico CityYauco

Bohemia

Albuquerque

Production | Sales Sales

SingaporeKuala Lumpur

Bangalore

Hanoi

TokyoBeijing Seoul

Hong KongBangkok

ShanghaiSuzhou

Production | Sales Sales

New OxfordAnn Arbor

Complementary Alliances & Acquisitions Add to Growth

27

Acquisitions | Alliances

27

Portfolio

20172000

Aseptic Technologies

Metroglas

LevTech

SAFC Biosciences

Raumedic

Südpack Medica

B. Braun Biotech International

OmnimarkCorning

c-LEcta

Umetrics

ABER

ProMetic

BlueSens

TC Tech

Biohit Liquid Handling

Lonza Cell Culture Media

TAP Biosystems

BD

AllPure

em-tec

BioOutsource

Cellca

kSep

ViroCyt

IntelliCyt

Essen BioScience

Toha Plast

Stedim Biosystems

Wave Biotech

Bayer Technology Services

NIR Online

Bosch Packaging

Trace Analytics

The Widest Product Portfolio Across the Biopharma Process Chain

Cell culture media Cell

Media Preparation

Seed Fermentation

ProductionFermentation

Cell Removal | Clarification

ViralClearance

y y

y yy

y

y

yy

yy

y

y y

y

yy

y

y

Antibodies Contaminents such as viruses

Simplified diagram

y y

yy

Media Preparation

Seed Fermentation

ProductionFermentation

Cell Removal Clarification

Capture Polishing VirusClearance

Downstream Processing Upstream Processing

Vaccines, monoclonalantibodies, ...

Process development

Portfolio

28

Support of processdevelopment Q3 2015

Testing in biosafety andbioanalytics Q2 2015

Small-scale single-use bioreactors Q4 2013

Cell culture mediaQ1 2013

Single-use technologyfor samplingQ2 2014

Bioprocess Portfolio Continuously Enhanced

Process Development Production

Software for bioprocessdata analysisQ2 2017

Single-usecentrifugesQ3 2016

29

Alliances Speed up Innovation

30

Portfolio

Development and supply partnership for novel polymer plastic films

Ready-to-use, prefilled media products formicrobiological applications

Single-use sensors for biomass measurement

New Products

31

Single-use Clarification SystemHigh flow rates, flexible scalability

Portfolio

Innovative Operating ConceptsFast and reliable results

Syringeless One-step FiltersSimple, multiplexing sample preparation

Modular Fermentation System Parallel use of up to eight su bioreactors

Strong R&D in Core Technologies

3232

Portfolio

Membranes, non-wovens Plastics processing: Injection

molding, extrusion, welding|gluing Sensors, automation & control Bioanalytics & cell biology Process analytics Mechatronics

Technologies

Biotechnology and biopharma Quality assurance and research

laboratories Technology integrationAlliances

Applications

1 2 Based on FY 2017 guidanceIncl. discontinued operation; 3333

Infrastructure

Investments into Infrastructure Foster Profitable Growth

Significant expansion of production capacities initiated in 2016; earlier and to a greater extent than initially planned due to continuing strong organic growth

Capacities at Yauco plant for single-use bags and filters will be more than doubled Expansion of operations at headquarters in Goettingen, e.g. additional membrane

capacities Further investments into digitalization (ERP, CRM, etc)

Capex ratio in %

8.8

201620142013120121

7.7

2015

~ 12-15

2017e2

11.79.1

10.1Expansion

Production facility in Yauco | Puerto Rico

New Sartorius Campus to Further Boost Innovative Strength and Efficiency

34

Consolidation of the two major Goettingen sites into one site

New lab instruments building in operation

Further expansion of filter and membrane production capacity

Building to foster an advanced and open work environment and to provide more space

Infrastructure

Agenda

35




04 Sartorius 2020

05 Appendix

Expansion in Stages of Sartorius Campus

36

Lab Instruments Manufacturing

Parking Lot

R&D Membrane production

CollegeFacility

Management

Main Entrance | Administration- under constr. -

Receiving area

Membranecasting machine

Bioprocess Solutions Manufacturing

Marketing | Cafeteria

- under constr. -

Infrastructure

Existing buildingsNew Buildings

Next Steps

37

Main Entrance | Administration

Marketing | Cafeteria

Under Construction

New main entrance and administration buildings:completion and relocation in Q3 2017

Forum with application labs, offices, cafeteria; expected to be operational by end of 2018

Infrastructure

38

Portfolio Bioprocess Solutions

Filtration Purification

39

Fluid Management Fermentation & Cell Culture Media

Portfolio Bioprocess Solutions

40

Portfolio Lab Products & Services

Lab Balances Pipettes

41

Lab Water Systems Further Lab Instruments


Bioanalytical Technologies

42

Lab Filtration Microbiological Quality Control


Questions & Answers

43

Disclaimer

This presentation contains statements concerning Sartorius Groups’ future performance. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because our assumptions harbor risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements.

Throughout this presentation, differences may be apparent as a result of rounding during addition.

44

powerpoint-präsentation · pdf filesecond world war. mid-90s positioning as ... ergonomic...

Documents